1,051 reports of this reaction
3.7% of all DOLUTEGRAVIR SODIUM reports
#2 most reported adverse reaction
ANXIETY is the #2 most commonly reported adverse reaction for DOLUTEGRAVIR SODIUM, manufactured by ViiV Healthcare Company. There are 1,051 FDA adverse event reports linking DOLUTEGRAVIR SODIUM to ANXIETY. This represents approximately 3.7% of all 28,565 adverse event reports for this drug.
Patients taking DOLUTEGRAVIR SODIUM who experience anxiety should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANXIETY is moderately reported among DOLUTEGRAVIR SODIUM users, representing a notable but not dominant share of adverse events.
In addition to anxiety, the following adverse reactions have been reported for DOLUTEGRAVIR SODIUM:
The following drugs have also been linked to anxiety in FDA adverse event reports:
ANXIETY has been reported as an adverse event in 1,051 FDA reports for DOLUTEGRAVIR SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANXIETY accounts for approximately 3.7% of all adverse event reports for DOLUTEGRAVIR SODIUM, making it one of the most commonly reported side effect.
If you experience anxiety while taking DOLUTEGRAVIR SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.